NCX 470 advances toward US, China NDA submissions for NCX 470 | Optometry Times - Clinical News

Published on January 3, 2026
NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.
Continue reading on website
Other news

FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report | Optometry Times - Clinical News

January 3, 2026
Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Optometry Times - Clinical News

January 4, 2026
K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.